You just read:

Foamix Announces Dosing of First Patient in Phase 3 Rosacea Clinical Trials for FMX103 Minocycline Foam 1.5%

News provided by

Foamix Pharmaceuticals Ltd.

Jun 12, 2017, 08:00 ET